Literature DB >> 18200776

[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease].

Yoshiki Yui1.   

Abstract

It is thought that coronary artery spasm is involved in the pathogenesis of coronary artery disease in a large proportion of Japanese patients. However, large-scale trial data in Japanese patients were lacking. The JMIC-B (Japan Multicenter Investigation for Cardiovascular Diseases-B) study conducted for Japanese hypertensive patients with coronary artery disease, compared the incidence of cardiac events (cardiac death or sudden death, myocardial infarction, hospitalization for angina pectoris or heart failure, serious arrhythmia, and coronary interventions) in patients receiving twice-daily nifedipine or an angiotensin-converting enzyme (ACE) inhibitor (enalapril, lisinopril or imidapril). There was a similar incidence of cardiac events in both treatment groups but exacerbation of angina pectoris in patients with a history of myocardial infarction was lower with nifedipine. Nifedipine appeared to be better than ACE inhibitor in inhibiting the progression of coronary atherosclerosis and the development of coronary artery stenosis as evidenced by quantitative coronary angiogram (QCA) analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18200776     DOI: 10.2165/00003495-200666991-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  7 in total

1.  Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients.

Authors:  Herwig-Ulf Meier-Kriesche; Akinlolu O Ojo; Alan B Leichtman; Jeffrey D Punch; Julie A Hanson; Diane M Cibrik; Bruce Kaplan
Journal:  J Am Soc Nephrol       Date:  2000-12       Impact factor: 10.121

2.  Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

Authors:  H Tedesco-Silva; M-C Bastien; L Choi; C Felipe; J Campestrini; F Picard; R Schmouder
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

Review 3.  Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.

Authors:  A M de Mattos; A J Olyaei; W M Bennett
Journal:  Am J Kidney Dis       Date:  2000-02       Impact factor: 8.860

4.  Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.

Authors:  A O Ojo; H U Meier-Kriesche; J A Hanson; A B Leichtman; D Cibrik; J C Magee; R A Wolfe; L Y Agodoa; B Kaplan
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

5.  Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.

Authors:  Karen L Hardinger; Daniel C Brennan; Jeffrey Lowell; Mark A Schnitzler
Journal:  Transpl Int       Date:  2004-10-29       Impact factor: 3.782

6.  Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.

Authors:  Klemens Budde; John Curtis; Gregory Knoll; Lawrence Chan; Hans-Hellmut Neumayer; Yodit Seifu; Michael Hall
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

7.  The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.

Authors:  Ronald P Pelletier; Baris Akin; Mitchell L Henry; Ginny L Bumgardner; Elmahdi A Elkhammas; Amer Rajab; Ronald M Ferguson
Journal:  Clin Transplant       Date:  2003-06       Impact factor: 2.863

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.